Immuno-oncology 14/03/2018 Improving Immuno-oncology Patient Response Rates Discover the four cornerstones of improving patient response rates. Combination therapies, precision medicine, trial design and regulatory challenges
Market access 08/02/2018 Video: How to Deliver Innovative Immunotherapies to Patients in the 'Real World' The infrastructure of delivering immuno-oncology therapies is equal in importance to the science. the industry must develop clear plans for delivery, pricing and reimbursement for commercialisation to be a reality
CAR-T 22/01/2018 15 Immuno-oncology Biotechs to Watch in 2018 We’re keeping tabs on the innovators and disruptors for you
Automation 06/03/2017 Systematic Automation of an Autologous Cellular Immunotherapy... As more and more approvals of immuno-oncology therapies become reality, how will these therapies be efficiently and sustainably...
Checkpoint inhibitors 07/02/2017 Innovation in the Development of Cancer Vaccines Cancer vaccines have gained increasing popularity since the US FDA approved the first cancer vaccine, sipuleucel-T, in 2010 and...
Precision medicine 07/02/2017 Interview: Developing Novel TNF/TNFR-based Compounds in the Fight... Thomas Hoeger, Ph.D., has been Chief Executive Officer of Apogenix since November 2005. Previously, he worked as a biotech...
Combination therapy 03/02/2017 Bioinformatics Modelling for Immunotherapy Precision medicine requires the delivery of individually adapted medical care based on the genetic characteristics of each...
Combination therapy 08/01/2017 Combination Therapy is the Future of Immuno-onclogy Tony joined Ablynx as Chief Scientific Officer in October 2013. In this role, he leads the company’s discovery, pharmacology,...
Combination therapy 08/01/2017 Interview: Research Strategies and New Clinical Trial Methodologies... Professor Dolores Schendel joined Medigene as Chief Scientific Officer in 2014 with the acquisition of Trianta...
Investment for advanced therapies 08/01/2017 Interview: Collaborations and Combinations with Donnie McGrath,... Donnie McGrath is Vice President, Head of Global search and evaluation in worldwide pharmaceutical finance at Bristol-Myers Squibb. He has been...
Combination therapy 08/01/2017 Interview: Harnessing the Power of the Innate Immune System Using... Dr. Klingemann is currently VP of research and development at NantKwest (Nasdaq: NK), the company he founded in 2002 as Zellerx based on the core...
Combination therapy 08/01/2017 Interview: Peregrine CEO Talks Big Pharma Partnerships and... Steve King was appointed President and CEO of Peregrine Pharmaceuticals in March 2003 and has led the company into three phase II clinical programs...
